ZLAB News and Press, Zai Lab Limited From 03/09/22

ZLAB was founded by Samantha Du, the Big Sister of China's emerging pharma industry. The company has an impressive pipeline. Recent US pushback on Chinese drugs makes me wonder whether the current low is an opportunity or a sign of trouble. For further details see: Zai L...

Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing. The company hopes heavy R&D spending can reduce its dependence on licensed products by improving its capacity to innovate. Zai Lab has placed mor...

Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%.&#x...

Zai Lab Limited (ZLAB) Q4 2021 Earnings Conference Call March 02, 2022 08:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson & Chief Executive Officer Alan Sandler - President & Head of Global Development, Oncology Harald Reinhart - Pr...

Zai Lab press release (NASDAQ:ZLAB): FY GAAP EPS of -$7.58 misses by $0.73. Revenue of $144.3M (+194.5% Y/Y) misses by $3.91M. For further details see: Zai Lab GAAP EPS of -$7.58 misses by $0.73, revenue of $144.3M misses by $3.91M

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the twelve months ended December 31, 2021,...

Zai Lab (NASDAQ:ZLAB) is scheduled to announce FY earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$6.86 and the consensus Revenue Estimate is $148.21M (+202.5% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. R...

ADT,AGEN,AKBA,ALBO,AMRN,AMRS,AXSM,AZO,OTCPK:BAYZF,BIDU,BLDR,BMO,BNS,BSY,CCCS,CHS,CMRX,CRON,DPZ,EHTH,EPZM,EVRI,FOUR,OTCQX:GTBIF,HGV,HOV,HRL,HTA,HZNP,IGT,IQ,ITCI,KSS,KTB,LILM,MANU,MCRB,MLCO,NFE,OTCQB:NLST,NUWE,OKE,PIRS,PLTK,PRGO,QTRX,REGI,RYTM,SE,SJM,TGT,TGTX,TLS,TWNK,UWMC,VFF,VRTV,WEN,WKHS,XXI...

Zai Lab (NASDAQ:ZLAB) said the Center for Drug Evaluation of China's National Medical Products Administration granted breakthrough therapy designation to repotrectinib for treating patients with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) who have not been treated wi...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical...